{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:06:52Z","timestamp":1789240012015,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a dangerous autoimmune condition that usually requires high-dose glucocorticoids with immunosuppressive agents. Although effective, long-term glucocorticoid use is associated with significant toxicity. Avacopan, a selective inhibitor of C5a receptors, has emerged as a possible glucocorticoid-sparing drug for AAV, potentially offering a safer, more specific approach to treat the disease. This systematic review and meta-analysis aimed to compare the efficacy and safety of avacopan and conventional glucocorticoid-containing regimens for the treatment of AAV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted in PubMed, Embase, Scopus, and the Cochrane Library between 2000 and 2025. Post hoc subgroup analyses, randomized controlled trials, and observational reports that compared avacopan with glucocorticoid regimens in GPA or MPA patients were included. The primary outcomes were remission at week 26 and sustained remission at week 52. The secondary outcomes were relapse rates, renal outcomes, adverse events, glucocorticoid toxicity, and health-related quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nine studies with 2080 patients were combined. Compared with glucocorticoids, avacopan was associated with noninferior remission rates at week 26 and significantly higher sustained remission rates at week 52 (RR\u2009=\u20091.02, 95% CI: 0.88\u20131.19). It was associated with significantly reduced glucocorticoid toxicity, fewer adverse events, and improved quality of life scores. Heterogeneity was low (I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20095.4%), which supported the consistency of the results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with standard glucocorticoid treatment, avacopan appears to offer a safer alternative with similar disease control and significantly reduced toxicity. These findings suggest a potential shift towards less toxic and more personalized approaches in AAV management, though further research is warranted to confirm these benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>PROSPERO CRD420251033866.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41927-025-00569-w","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:36:51Z","timestamp":1759491411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of avacopan in the treatment of ANCA-associated vasculitis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5166-3515","authenticated-orcid":false,"given":"Khaled","family":"Aldhuaina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5226-3254","authenticated-orcid":false,"given":"Khawla","family":"Alghanim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"569_CR1","doi-asserted-by":"crossref","unstructured":"Yates M, Watts R. ANCA-associated vasculitis. Clinical medicine. London, England; 2017 Feb. p. 60\u201364. PubMed PMID: 28148583. Pubmed Central PMCID: PMC6297586. Epub 2017\/02\/06. eng.Vol. 17(1).","DOI":"10.7861\/clinmedicine.17-1-60"},{"key":"569_CR2","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.2147\/JIR.S284768","volume":"15","author":"K Austin","year":"2022","unstructured":"Austin K, Janagan S, Wells M, Crawshaw H, McAdoo S, Robson JC. ANCA associated vasculitis subtypes: recent insights and future perspectives. J Inflamm Res. 2022;15:2567\u201382. PubMed PMID: 35479831. Pubmed Central PMCID: PMC9037725. Epub 2022\/04\/29. eng.","journal-title":"J Inflamm Res"},{"issue":"3","key":"569_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/ckj\/sfv020","volume":"8","author":"OO Rowaiye","year":"2015","unstructured":"Rowaiye OO, Kusztal M, Klinger M. The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis. Clin Kidney J. 2015, Jun;8(3):343\u201350. PubMed PMID: 26034600. Pubmed Central PMCID: PMC4440467. Epub 2015\/06\/03. eng.","journal-title":"Clin Kidney J"},{"issue":"1","key":"569_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2478\/rir-2023-0003","volume":"4","author":"XJ Sun","year":"2023","unstructured":"Sun XJ, Li ZY, Chen M. Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatol And Immunol Res. 2023, Mar;4(1):11\u201321. PubMed PMID: 37138650. Pubmed Central PMCID: PMC10150877. Epub 2023\/05\/04. eng.","journal-title":"Rheumatol And Immunol Res"},{"issue":"6","key":"569_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/ki.2010.472","volume":"79","author":"B Wilde","year":"2011","unstructured":"Wilde B, Van Paassen P, Witzke O, Tervaert JWC. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int. 2011; 2011\/03\/02\/; 79(6):599\u2013612.","journal-title":"Kidney Int"},{"issue":"1","key":"569_CR6","doi-asserted-by":"publisher","first-page":"101828","DOI":"10.1016\/j.berh.2023.101828","volume":"37","author":"A Morris","year":"2023","unstructured":"Morris A, Geetha D. Advances in remission induction therapy for ANCA-associated vasculitis. Best Pract Res Clin rheumatol. 2023; 2023\/03\/01\/; 37(1):101828.","journal-title":"Best Pract Res Clin rheumatol"},{"issue":"1","key":"569_CR7","doi-asserted-by":"publisher","first-page":"105768","DOI":"10.1016\/j.jbspin.2024.105768","volume":"92","author":"X Pu\u00e9chal","year":"2025","unstructured":"Pu\u00e9chal X. Update on targeted treatments for ANCA-associated vasculitis. Jt Bone Spine. 2025; 2025\/01\/01\/; 92(1):105768.","journal-title":"Jt Bone Spine"},{"issue":"2","key":"569_CR37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/ard-2023-224623","volume":"83","author":"F Delestre","year":"2024","unstructured":"Delestre F, Charles P, Karras A, Pagnoux C, N\u00e9el A, Cohen P, et al. Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Ann Rheum Dis. 2024; 2024\/02\/01\/; 83(2):233\u201341.","journal-title":"Ann Rheum Dis"},{"key":"569_CR8","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1002\/cncr.28318","volume":"119","author":"P Strati","year":"2013","unstructured":"Strati P, Burger J, Ferrajoli A, Tam C, Lerner S, O\u2019Brien S. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia analysis of persistent and new-onset cytopenia. Cancer. 2013; 2013, 11\/01; 119:3805\u201311.","journal-title":"Cancer"},{"key":"569_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S142471","volume":"14","author":"K Kridin","year":"2018","unstructured":"Kridin K. Emerging treatment options for the management of pemphigus vulgaris. Ther Clin Risk Manag. 2018;14:757\u201378. PubMed PMID: 29740210. Pubmed Central PMCID: PMC5931200. Epub 2018\/05\/10. eng.","journal-title":"Ther Clin Risk Manag"},{"key":"569_CR10","doi-asserted-by":"crossref","unstructured":"King C, Harper L. Avoidance of harm from treatment for ANCA-associated vasculitis. Current treatment options in rheumatology. 2017;3(4):230\u201343. PubMed PMID: 29201630. Pubmed Central PMCID: PMC5694500. Epub 2017\/12\/05. eng.","DOI":"10.1007\/s40674-017-0082-y"},{"key":"569_CR11","doi-asserted-by":"publisher","first-page":"i85","DOI":"10.1093\/ndt\/gfy104.FP167","volume":"33","author":"D Jayne","year":"2018","unstructured":"Jayne D, Potarca A, Schall T, Hilson J, Becker P. Adverse events with glucocorticoid standard of care versus avacopan in ANCA-associated vasculitis: observations from the clear trial. Nephrol Dial transplant. 2018;33:i85\u20136.","journal-title":"Nephrol Dial transplant"},{"issue":"6","key":"569_CR12","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ekir.2024.03.022","volume":"9","author":"R Zonozi","year":"2024","unstructured":"Zonozi R, Aqeel F, Le D, Cortazar FB, Thaker J, Ramirez MJZ, et al. Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int Rep. 2024;9(6):1783\u201391.","journal-title":"Kidney Int Rep"},{"issue":"9","key":"569_CR13","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1016\/j.ekir.2024.07.007","volume":"9","author":"J Zimmermann","year":"2024","unstructured":"Zimmermann J, Sonnemann J, Jabs WJ, Sch\u00f6nermarck U, Vielhauer V, Bieringer M, et al. Avacopan in anti-neutrophil cytoplasmic autoantibodies-associated vasculitis in a real-world setting. Kidney Int Rep. 2024; 2024\/09\/01\/; 9(9):2803\u201308.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"569_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/cei.13515","volume":"202","author":"G Trivioli","year":"2020","unstructured":"Trivioli G, Vaglio A. The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy. Clin Exp Immunol. 2020, Dec;202(3):403\u201306. PubMed PMID: 32946609. Pubmed Central PMCID: PMC7670158. Epub 2020\/09\/19. eng.","journal-title":"Clin Exp Immunol"},{"issue":"Supplement_3","key":"569_CR15","doi-asserted-by":"publisher","first-page":"gfaa146.LB003","DOI":"10.1093\/ndt\/gfaa146.LB003","volume":"35","author":"D Jayne","year":"2020","unstructured":"Jayne D, Merkel P, Yue H, Schall TJ, Kelleher C, Bekker P. LB003 a randomized, double-blind, active controlled study of avacopan in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial transplant. 2020;35(Supplement_3):gfaa146.LB003.","journal-title":"Nephrol Dial transplant"},{"issue":"9","key":"569_CR16","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DR Jayne","year":"2017","unstructured":"Jayne DR, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756\u201367.","journal-title":"J Am Soc Nephrol"},{"key":"569_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/DDDT.S341842","volume":"19","author":"JR Van Leeuwen","year":"2025","unstructured":"Van Leeuwen JR, Quartuccio L, Draibe JB, Gunnarson I, Sprangers B, Teng YKO. Evaluating avacopan in the treatment of ANCA-associated vasculitis: design, development and positioning of therapy. Drug Des Devel Ther. 2025;19:23\u201337. PubMed PMID: 39803605. Pubmed Central PMCID: PMC11717651. Epub 2025\/01\/13. eng.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"569_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41927-025-00456-4","volume":"9","author":"G Tagami","year":"2025","unstructured":"Tagami G, Yamaguchi M, Sugiyama H, Kinashi H, Imai K, Kamiya K, et al. Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan. BMC Rheumatol. 2025, Jan, 23;9(1):8. PubMed PMID: 39844309. Pubmed Central PMCID: PMC11756139. Epub 2025\/01\/23. eng.","journal-title":"BMC Rheumatol"},{"key":"569_CR19","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1001\/jama.2021.6615","volume":"325","author":"S Furuta","year":"2021","unstructured":"Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. JAMA. 2021,06\/01; 325:2178.","journal-title":"JAMA"},{"issue":"11","key":"569_CR20","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/acr2.11185","volume":"2","author":"PA Merkel","year":"2020","unstructured":"Merkel PA, Niles J, Jimenez R, Spiera RF, Rovin BH, Bomback A, et al. Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open rheumatol. 2020;2(11):662\u201371.","journal-title":"ACR Open rheumatol"},{"key":"569_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/B978-0-12-384864-2.00018-4","volume-title":"Statistics in medicine","author":"RH Riffenburgh","year":"2012","unstructured":"Riffenburgh RH. Chapter 18-sample size estimation and meta-analysis. In: Riffenburgh R, editor. Statistics in medicine. San Diego: Academic Press 2012; p. 365\u201391."},{"key":"569_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","volume":"14","author":"AM Methley","year":"2014","unstructured":"Methley AM, Campbell S, Chew-Graham C, McNally R, Pico C-S-S. PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14:579.","journal-title":"BMC Health Serv Res"},{"key":"569_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/9781119536604.ch8","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JP Higgins","year":"2019","unstructured":"Higgins JP, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. In: Jpt H, Thomas J, Chandler J, Cumpston M, Li T, Mj P, et al.editors. Cochrane handbook for systematic reviews of interventions. Hoboken: Wiley; 2019; p. 205\u201328."},{"key":"569_CR24","first-page":"i 4919","volume":"355","author":"P J\u00fcni","year":"2016","unstructured":"J\u00fcni P, Loke Y, Pigott T, Ramsay C, Regidor D, Rothstein H, et al. Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance. Br Med J. 2016;355:i 4919.","journal-title":"Br Med J"},{"issue":"5","key":"569_CR25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jclinepi.2010.09.016","volume":"64","author":"JO Friedrich","year":"2011","unstructured":"Friedrich JO, Adhikari NKJ, Beyene J. Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods. J Clin Epidemiol. 2011;64(5):556\u201364.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"569_CR38","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00134-023-07163-z","volume":"49","author":"HJ De Grooth","year":"2023","unstructured":"De Grooth HJ, Parienti JJ. Heterogeneity between studies can be explained more reliably with individual patient data. Intensive Care Med. 2023, Oct;49(10):1238\u201341. PubMed PMID: 37466672. Pubmed Central PMCID: PMC10556177. Epub 2023\/07\/19. eng.","journal-title":"Intensive Care Med"},{"issue":"2","key":"569_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina TB, S\u00e1nchez-Meca J, Mar\u00edn-Mart\u00ednez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193.","journal-title":"Psychol Methods"},{"issue":"7","key":"569_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DR Jayne","year":"2021","unstructured":"Jayne DR, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599\u2013609.","journal-title":"N Engl J Med"},{"key":"569_CR28","first-page":"gfaa146","volume":"1","author":"D Jayne","year":"2022","unstructured":"Jayne D, Merkel P, Yue H, Schall TJ, Kelleher C, Bekker P. LB003 a randomized, double-blind, active controlled study of avacopan in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dialysis transplant. 2022; Jun;1;35(Supplement_3): gfaa146\u2013LB003.","journal-title":"Nephrol Dialysis transplant"},{"issue":"2","key":"569_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/ard-2023-224816","volume":"83","author":"D Geetha","year":"2024","unstructured":"Geetha D, Dua A, Yue H, Springer J, Salvarani C, Jayne D, et al. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial. Ann Rheum Dis. 2024;83(2):223\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"Supplement_1","key":"569_CR30","doi-asserted-by":"publisher","first-page":"gfae069\u20130135","DOI":"10.1093\/ndt\/gfae069.135","volume":"39","author":"A Kronbichler","year":"2024","unstructured":"Kronbichler A, Geetha D, Bray S, Gurlin RE, Merkel PA, Jayne DR. # 386 Avacopan versus prednisone taper in newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis in the advocate trial. Nephrol Dial transplant. 2024;39(Supplement_1):gfae069\u20130135\u2013386.","journal-title":"Nephrol Dial transplant"},{"issue":"3","key":"569_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/mr\/roab104","volume":"32","author":"M Harigai","year":"2022","unstructured":"Harigai M, Takada H. Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitis. Mod rheumatol. 2022;32(3):475\u201383.","journal-title":"Mod rheumatol"},{"issue":"3","key":"569_CR32","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1016\/S2665-9913(23)00030-9","volume":"5","author":"NJ Patel","year":"2023","unstructured":"Patel NJ, Jayne DRW, Merkel PA, Bekker P, Zhang Y, Yue H, et al. Glucocorticoid toxicity index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial. The Lancet rheumatol. 2023, Mar;5(3):e130\u20138. PubMed PMID: 38251609. Epub 2024\/01\/22. eng.","journal-title":"The Lancet rheumatol"},{"key":"569_CR33","unstructured":"Strand V, Jayne DRW, Horomanski A, Yue H, Bekker P, Merkel PA, et al. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial. The Lancet RheumatOl. 2023; 2023\/08\/01\/; 5(8):e451\u201360."},{"issue":"2","key":"569_CR34","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1124\/pharmrev.120.000072","volume":"73","author":"P Garred","year":"2021","unstructured":"Garred P, Tenner AJ, Mollnes TE. Therapeutic targeting of the complement system: from rare diseases to pandemics. Pharmacol Rev. 2021; Apr;73(2):792\u2013827. PubMed PMID: 33687995. Pubmed Central PMCID: PMC7956994 Pharma\/UCB. A.J.T. is a consultant for Montis. Epub 2021\/03\/11. eng.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"569_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"JH Wang","year":"2024","unstructured":"Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024; 2024\/04\/03; 9(1):78.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"569_CR36","doi-asserted-by":"publisher","first-page":"e11795","DOI":"10.1002\/acr2.11795","volume":"7","author":"U Specks","year":"2025","unstructured":"Specks U, Spiera RF, Fussner LA, Lebovics R, Bray S, Gurlin RE, et al. Treatment with avacopan in patients with respiratory tract manifestations of antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open rheumatol. 2025, Jan;7(1):e11795. PubMed PMID: 39854178. Pubmed Central PMCID: PMC11760992. Epub 2025\/01\/24. eng.","journal-title":"ACR Open rheumatol"},{"issue":"16;83","key":"569_CR39","first-page":"ard","volume":"3","author":"B Hellmich","year":"2023","unstructured":"Hellmich B, Alamo B, Schirmer J, Berti A, Blockmans D, Cid Xutgla M, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023;3(16;83):ard-2022.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"569_CR40","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s11897-022-00556-z","volume":"19","author":"AL Huang","year":"2022","unstructured":"Huang AL, Hendren N, Carter S, Larsen C, Garg S, La Hoz R, et al. Biomarker-based assessment for infectious risk before and after heart transplantation. Curr Heart Fail Rep. 2022, Aug;19(4):236\u201346. PubMed PMID: 35597863. Pubmed Central PMCID: PMC9124010. Epub 2022\/05\/22. eng.","journal-title":"Curr Heart Fail Rep"},{"key":"569_CR41","unstructured":"Tesar V, Hartinger JM, Hruskova Z. Avacopan as an add-on therapy for ANCA-associated vasculitis: a pharmacological overview. Expert review of clinical pharmacology. 2024, Dec;17(12):1099\u2013113. PubMed PMID: 39611585. Epub 2024\/11\/29. eng."}],"updated-by":[{"DOI":"10.1186\/s41927-025-00609-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000}}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00569-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00569-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00569-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:30:11Z","timestamp":1781609411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41927-025-00569-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00569-w","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s41927-025-00609-5","URL":"https:\/\/doi.org\/10.1186\/s41927-025-00609-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}